A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.
The pharmaceutical company AstraZeneca retracted a paper and acknowledged that some preclinical data were falsified regarding its developmental agent acalabrutinib, which is under investigation for use in a number of malignancies.
Small-cell lung cancer patients with high tumor burden treated with immunotherapy had greater objective response rate, progression-free survival, and overall survival compared with patients with medium or low tumor burden.
Quality of life was not improved with the use of early palliative care for patients recently diagnosed with malignant pleural mesothelioma, according to data presented at the World Conference on Lung Cancer.
Extending the platinum-free interval following disease progression in ovarian cancer with a non-platinum agent does not improve outcomes over the standard practice of using a platinum-based chemotherapy, according to a prospective trial.
A new randomized trial found that neoadjuvant trastuzumab/pertuzumab alone yields a substantially worse rate of pathologic complete response compared with paclitaxel plus the two anti-HER2 agents for women with early HER2-positive breast cancer.
This article includes a succinct review of current research into exercise in the cancer setting and a discussion of the American College of Sports Medicine exercise recommendations for cancer survivors. Common acute, long-term, and late effects of cancer and its treatment are also described in the context of ways in which these side effects impact the ability to exercise.
In this interview we discuss health disparities in cancer care, how redesigning cancer clinical trials can address some of these disparities, and goals for the “next generation” of cancer health disparities research.
This articles reviews the mechanisms of sexual dysfunction that occurs after breast cancer, offers some practical guidance on how to discuss this effectively with patients, and reviews the data and recommendations for optimizing management.
Through this vital new partnership, the Society for Integrative Oncology and ONCOLOGY seek to make integrative medicine part of standard clinical oncology practice, and to help physicians and patients make informed decisions about complementary and alternative medicine to maximize benefits and minimize harms.
While the incidence of irAEs is relatively low, the absolute number of patients receiving immune checkpoint inhibitors is steadily increasing. Thus, it is likely that, with time, larger numbers of patients will develop irAEs, including pneumonitis.